Tarsus Pharmaceuticals, Inc.
NASDAQ:TARS
Overview | Financials
Company Name | Tarsus Pharmaceuticals, Inc. |
Symbol | TARS |
Currency | USD |
Price | 52.91 |
Market Cap | 2,022,585,279 |
Dividend Yield | 0% |
52-week-range | 18.99 - 56.77 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Bobak R. Azamian M.D. |
Website | https://www.tarsusrx.com |
An error occurred while fetching data.
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD